Showing results (261-270 of 567) with videos related to
Sort By:
Pageof 57
Epilepsia Open|October 30, 2021
Infantile-onset myoclonic developmental and epileptic encephalopathy: A new RARS2 phenotypeGuillem de Valles-Ibáñez, Michael S Hildebrand, Melanie Bahlo, et al.Archives of Neurology|May 11, 2011
Glucose transporter 1 deficiency as a treatable cause of myoclonic astatic epilepsySaul A Mullen, Carla Marini, Arvid Suls, et al.The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|February 22, 2023
Retinal Dysfunction in a Mouse Model of HCN1 Genetic EpilepsyDa Zhao, Paulo Pinares-Garcia, Chaseley E McKenzie, et al.Neurology|November 2, 2022
Complications of Influenza A or B Virus Infection in Individuals With SCN1A-Positive Dravet SyndromeKatherine B Howell, Sophie Butcher, Amy L Schneider, et al.Epilepsy Research|November 28, 2012
Do mutations in SCN1B cause Dravet syndrome?Young Ok Kim, Leanne Dibbens, Carla Marini, et al.Developmental Medicine and Child Neurology|June 10, 2021
Severe speech impairment is a distinguishing feature of FOXP1-related disorderRuth O Braden, David J Amor, Simon E Fisher, et al.Epilepsia|May 12, 2018
A population-based cost-effectiveness study of early genetic testing in severe epilepsies of infancyKatherine B Howell, Stefanie Eggers, Kim Dalziel, et al.Epilepsy Currents|September 18, 2020
The Impact of COVID-19 on Epilepsy Care: A Survey of the American Epilepsy Society MembershipDara V F Albert, Rohit R Das, Jayant N Acharya, et al.Epilepsia|April 17, 2013
SCN1A testing for epilepsy: application in clinical practiceShinichi Hirose, Ingrid E Scheffer, Carla Marini, et al.Journal of Paediatrics and Child Health|September 23, 2020
Protocol for a single patient therapy plan: A randomised, double-blind, placebo-controlled N-of-1 trial to assess the efficacy of cannabidiol in patients with intractable epilepsyKatherine S Ong, John B Carlin, Michael Fahey, et al.Pageof 57